ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
0,00%
Bitcoin
64.325,00
0,68%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AVEO Pharmaceuticals Inc (AVEO)

  7. AVEO Pharmaceuticals Inc (AVEO) News

AVEO

AVEO Pharmaceuticals (AVEO)

AVEO Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AVEO
DatumZeitQuelleÜberschriftSymbolFirma
28/03/202420h22GlobeNewswire Inc.CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeNASDAQ:AVEOAVEO Pharmaceuticals Inc
25/03/202413h10GlobeNewswire Inc.AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeNASDAQ:AVEOAVEO Pharmaceuticals Inc
06/02/202414h10GlobeNewswire Inc.AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The OncologistNASDAQ:AVEOAVEO Pharmaceuticals Inc
16/01/202413h30GlobeNewswire Inc.AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)NASDAQ:AVEOAVEO Pharmaceuticals Inc
30/01/202322h08Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:AVEOAVEO Pharmaceuticals Inc
24/01/202312h07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AVEOAVEO Pharmaceuticals Inc
24/01/202312h07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AVEOAVEO Pharmaceuticals Inc
24/01/202312h07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202323h20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202323h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202323h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202323h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202323h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202323h05Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h47Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h46Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h44Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h43Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h42Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h40Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h40Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h38Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202322h35GlobeNewswire Inc.LG Chem Completes Acquisition of AVEO OncologyNASDAQ:AVEOAVEO Pharmaceuticals Inc
18/01/202314h41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
05/01/202322h59Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
23/12/202222h02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
22/12/202222h47Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
02/12/202215h07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
02/12/202215h05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
25/11/202214h09Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AVEO

Kürzlich von Ihnen besucht

NYSE
MRK
Merck
DBI
TDXP
Tec DAX
PM
XAUUSD
Gold vs US Dollar
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
FX
EURGBP
Euro vs Sterling
NYSE
DIS
Walt Disney
TG
MBG
MercedesBenz
TG
LHA
Deutsche Lufthansa
CCOM
US500
US 500
NYSE
KO
Coca Cola
TG
432
Arbor Metals
COIN
BTCUSD
Bitcoin
TG
DTE
Deutsche Telekom
TG
NOV
Novo Nordisk
TG
D7G
Nel ASA
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten